Background {#Sec1}
==========

X-linked agammaglobulinaemia (XLA, OMIM: 300755) is a rare immunodeficiency disease caused by defective B cell development and extremely low numbers of mature B cells \[[@CR1]\]. The main clinical symptom of XLA is recurrent severe infection \[[@CR2]\]. The estimated incidence of XLA is approximately 1:250,000, and the causative mutations are located in the Bruton's tyrosine kinase (*BTK*) gene \[[@CR3], [@CR4]\]. The *BTK* gene is located at Xq21.3-Xq22; the gene is 37.5 kb and comprises 19 exons. The protein encoded by the gene is a cytoplasmic tyrosine kinase that contains five different functional domains: pleckstrin homology (PH), Tec homology (TH), Src homology 3 (SH3), SH2, and kinase (TK) domains \[[@CR5]\]. The N-terminal PH domain binds to membrane phosphatidylinositol (3,4,5)-trisphosphate (PIP3), and the TH, SH3, and SH2 domains are involved in protein-protein interactions. Y223 and Y551 are two tyrosine phosphorylation sites in the SH3 and TK domains, respectively \[[@CR6]\]. BTK activates many major signaling pathways, including the phosphoinositol-3 kinase (PI3K)-AKT pathway, phospholipase-C (PLC), protein kinase C, and nuclear factor kappa B (NF-kB) \[[@CR7]\]. BTK also participates in B cell receptor (BCR) engagement by antigens and induces a range of protein interactions as well as recruitment of signaling molecules, resulting in B cell survival, proliferation and differentiation and the production of antibodies \[[@CR8]\].

Methods {#Sec2}
=======

Patients and study design {#Sec3}
-------------------------

From 2016 to 2019, 22 male XLA patients from 22 unrelated families in Henan Province of China were enrolled in this study. XLA was diagnosed according to the diagnostic criteria for XLA developed by the Joint European Society for Immunodeficiencies Committee \[[@CR9]\]. After determining *BTK* gene mutations in the proband, the fetal villi or amniotic fluid of high-risk pregnant women were used for prenatal diagnosis. Mutation analysis of the fetal genome was carried out by DNA sequencing. The study was approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University. The patients 16 years of age and over signed informed consent forms. A written informed consent was obtained from the parents or legal guardians of any participant under the age of 16.

Routine immunological analysis {#Sec4}
------------------------------

Serum was separated from 3 mL of peripheral venous blood without anticoagulant treatment. Immunoglobulins were examined by rate scatter immunoturbidimetry using a Siemens BN II automatic protein analyzer. CD19+ was detected with a FACSCanto II flow cytometer using 3 mL of EDTA-treated blood.

Genetic testing {#Sec5}
---------------

Genomic DNA was extracted from 2 mL of EDTA-treated peripheral venous blood from each proband and mother using Blood DNA Midi Kit D3494 (Omega Biotek, USA) with nucleic acid automatic extraction equipment (Eppendorf epMotion 5075 m, Germany). Amniotic fluid cell DNA was extracted and cleaned using QIAamp Blood DNA Midi Kit (250, Germany) and Genomic DNA Clean & Concentrator (Zymo Research, USA). The DNA sequence of the *BTK* gene obtained from the NCBI database was used as a reference. PCR amplification was carried out using relevant primers (Table [S1](#MOESM1){ref-type="media"}) under conventional PCR conditions. The PCR product was confirmed by 2% agarose gel and was purified for two-way sequencing. The sequencing product was separated using an ABl3130xl gene sequencing machine. The sequencing results were compared by Chromas software to identify mutation loci. For novel mutations, Genome Aggregation Database (gnomAD) and the UCSC database were used. In addition, the large the *BTK* gene deletion was assessed using QuantStudio 5 Real-Time PCR System (ABI, USA).

Results {#Sec6}
=======

Clinical characteristics {#Sec7}
------------------------

Twenty-two families were enrolled in this study. The mean age of onset of XLA was 3 years, and the mean age of diagnosis was 7 years. The clinical infections present at the time of diagnosis are shown in Table [1](#Tab1){ref-type="table"}. Of the types of infections, respiratory infection was the most common (*n* = 19, 78.9%), followed by sinusitis, sepsis, otitis media and central nervous system infection. Table 1Characteristics of 22 XLA male patientsPatientsAge at onset, yAge at diagnosis, yCD19+ B cells, %IgG,g/l (5.66--14.25)IgA,g/l(0.8--5)IgM,g/l (0.3--2.09)Clinical presentationP1121(6--25)0.5100.0600.060Pneumonia, herpetic stomatitisP2350(6--25)\< 0.810\< 0.3300.300Mycoplasmal pneumoniaeP36 months40.00(5.0--18.0)0.1700.0300.220Sepsis, bilateral otitis media, sepsisP414151(6--25)\< 1.770\< 0.060\< 0.080Infectious diarrhea, dystrophic anemiaP57 months10 months...0.2400.0300.200Bronchopneumonia, gastrointestinal dysfunctionP6926...0.260.........P7270.23(6--25)\< 0.020\< 0.070\< 0.150Central nervous system infection, epilepsy, upper respiratory infection, hydronephrosisP8390.0(5.0--18.0)0.7100.0100.130Bronchopneumonia, bronchiectasis, airway hyperresponsiveness, sinusitisP93130.00(5.0--18.0)4.4000.4600.570Bronchopneumonia, pleural effusionP1020 days40.00(5.0--18.0)5.6400.1100.050Pneumonia, bronchiectasisP11550(6--25)\< 0.550\< 0.050\< 0.200Acute upper respiratory tract infection, viral encephalitis, pneumoniaP12781(6--25)\< 0.800\< 0.090\< 0.220BronchopneumoniaP13330.00(5.0--18.0)1.5000.7900.760Bronchopneumonia, dilated cardiomyopathy, Vitamin k deficiency, Upper respiratory tract infection, sepsisP14270.04(5.0--18.0)............P1523.5...0.1000.0000.040PneumoniaP161100.00(5.0--18.0)0.4100.0200.040Recurrent cough, bronchiectasis, pulmonary infection, hepatitis B virus carrierP179 months20(6--25)\< 0.100\< 0.090\< 0.18PneumoniaP18150.00(5.0--18.0)0.1000.0200.040BronchopneumoniaP1928...\< 2.090\< 0.000\< 0.000Pulmonary infection, bronchiectasis, sinusitisP2033...\< 0.030\< 0.000\< 0.060Pneumonia, iron-deficiency anemia, hypoalbuminemiaP216 months8...0.300.........P226 months50.03(5.0--18.0)\< 0.740\< 0.000\< 0.130Perianal abscess, anal fistula, chronic nasosinusitis, otitis media, sepsis

Immunological features {#Sec8}
----------------------

As indicated in Table [1](#Tab1){ref-type="table"}, all patients exhibited a very low percentage of CD19+ B cells and serum immunoglobulin (IgG, IgA, and IgM) levels at diagnosis. No patients got intravenous immunoglobulin (IVIG) substitution therapy before diagnosis. The percentage of CD19+ B cells in all patients was 0--1%, and ten of the sixteen patients had a B cell proportion of 0%. Nineteen of 21 patients had serum IgG concentrations of less than 2 g/L; two of 21 patients had serum IgG concentrations greater than 2 g/L but less than 5.66 g/L. The concentration of serum IgA (*n* = 19) in all patients was less than 0.8 g/L, and that of serum IgM in all patients was less than 0.3 g/L, except for patients 2, 9 and 13.

*BTK* mutation analysis {#Sec9}
-----------------------

To confirm the diagnosis, mutation analysis of the *BTK* gene was performed (Table [2](#Tab2){ref-type="table"}). Analysis of exons 1 to 19 and the flanking intronic regions revealed the presence of 22 different mutations in the 22 patients from 22 unrelated families, including 8 missense mutations, 4 nonsense mutations, 3 splice-site mutations, 5 frameshifts resulting in secondary premature termination, and 2 large deletions. Among them, 6 are novel mutations, including 2 missense mutations (c.23G \> T and c.112 T \> C), 2 frameshift mutations (c.522_523insC and c.1060delA), 1 large deletion (deletion of exon 2 to 5), and 1 splice-site mutation (c.1631 + 2 T \> C). Genetic analysis of carrier status was conducted in 16 families with definitive *BTK* gene mutations, and 14 carriers with *BTK* gene mutations were identified. The mothers in the other six families were not tested because of death, divorce or subjective will. The pedigree of the above 22 families is shown in Fig. [1](#Fig1){ref-type="fig"} and Table [2](#Tab2){ref-type="table"} (the right-most column). Table 2*BTK* gene mutations in 22 XLA patients from 22 unrelated familiesFamilyPatientLocalizationDomainNucleotide substitutionsAmino acid changeType of mutationMother statusPedigree ^**c**^F1P1Exon 2PHc.23G \> T ^**a**^S8Imissense mutationNEAF2P2Exon 2PHc.83G \> AR28Hmissense mutationNEAF3P3Exon 2PHc.112 T \> C ^a^S38Pmissense mutationNMDBF4P4Exon 2PHc.126 T \> GY42\*nonsense mutationcarrierCF5P5Exon 6THc.460 T \> CC154Rmissense mutationcarrierDF6P6Intron 6THc.520 + 5G \> ASplicingSplicingNE...F7P7Exon 7Proline richc.522_523insC ^a^P177Tfs\*17FS (stop)carrierEF8P8Exon 8SH3c.763C \> TR255\*nonsense mutationNMDFF9P9Exon 10SH2c.862C \> TR288Wmissense mutationcarrierDF10P10Exon 11SH2c.922_923delGA ^b^D308Lfs\*14FS (stop)NEGF11P11Exon 12SH2c.1060delA ^a\ b^T354Pfs\*49FS (stop)carrierHF12P12Exon 13SH2c.1117C \> AL373Imissense mutationcarrierIF13P13Exon 14Kinasec.1184G \> AW395\*nonsense mutationNEJF14P14Exon 15Kinasec.1439delGG480Afs\*4FS (stop)carrierCF15P15Intron 16Kinasec.1631 + 1G \> T ^b^SplicingSplicingcarrierHF16P16Intron 16Kinasec.1631 + 2 T \> C ^a^SplicingSplicingNEKF17P17Exon 17Kinasec.1679delCP560Qfs\*10FS (stop)carrierLF18P18Exon 17Kinasec.1684C \> T ^b^R562Wmissense mutationcarrierMF19P19Exon 18Kinasec.1901G \> AW634\*nonsense mutationcarrierCF20P20Exon 19Kinasec.1931 T \> C ^b^F644Smissense mutationcarrierNF21P21......Deletion of exon 2 to 5 ^a\ b^large deletionlarge deletioncarrierHF22P22......Deletion of exon 6 to 10large deletionlarge deletioncarrierOFS (stop): frameshift resulting in secondary premature termination*NE* not examined, *NMD* no mutation detected^a^: novel mutation^b^:represent prenatal pedigree^c^: Each letter (A-O) represents a type of the pedigree. All pedigrees of the families can be found in Fig. [1](#Fig1){ref-type="fig"}\*: represent the terminatorFig. 1Heredity map of the family with the proband. (Each letter (A-O) represents a type of the pedigree. The details can be found in the right-most column of Table [2](#Tab2){ref-type="table"})

Four of 22 mutations identified in the *BTK* gene are located in the PH domain, 2 in the TH domain, 1 in the SH3 domain, 4 in the SH2 domain and 8 in the kinase domain. In addition, 2 mutations (the large exon deletion) are predicted to affect the translation of the protein.

Prenatal diagnosis {#Sec10}
------------------

Six families (F10, F11, F15, F18, F20 and F21) who received prenatal diagnosis (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}); we confirmed that the fetal villi or amniotic fluid samples had not been contaminated by the material from the mother. The male fetus in Family 10 did not carry the p.D308Lfs\*14 mutation, and the male fetus in Family 15 did not carry the c.1631 + 1G \> T splicing mutation. In Family 20, the female fetus did not carry the c.1931 T \> C mutation, and in Family 21, the female fetus did not carry the large deletion mutation (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). None of these four fetuses are likely to develop XLA patients in the future. The above four families chose to continue the pregnancy after genetic counseling. Umbilical cord blood was collected for genetic diagnosis after full-term delivery, and the results were consistent with the prenatal diagnosis. According to telephone follow-up after 1 year, the general development of the infants was normal. Male fetuses in Family 11 and Family 18 carried p.T354Pfs\*49 and p.R562W mutations, respectively. After genetic counseling, the pregnant woman in Family 18 chose to terminate the pregnancy, and DNA analysis of the tissues was consistent with the prenatal diagnosis results. Conversely, the pregnant woman in Family 11 chose to continue the pregnancy. Fig. 2Sequence chromatograms of *BTK* variants in five prenatal pedigrees and controlsFig. 3Real-time PCR results of *BTK* gene in Family 21 and the male control. (The deletion of exon 2, 4 and 5 was hemizygous in the affected proband, and heterozygous in the mother. The female fetus and the male control did not carry the large deletion mutation)

Discussion {#Sec11}
==========

Here, we review the clinical data of 22 male XLA patients from 22 unrelated Chinese families in Henan Province. Our results showed that all patients had typical clinical presentations, including recurrent infections and hypogammaglobulinemia with a significant decrease or near complete absence of B cells in the peripheral blood. Respiratory infection was the main clinical feature of the patients in this study, consistent with previous findings \[[@CR10]\]. The mean age at diagnosis was 7 years, which is higher than in a reported series from the United States \[[@CR11]\] but similar to the series reported from other provinces in China \[[@CR12]\]. There was also a considerable delay in the diagnosis of these patients, especially Patient 6, whose diagnosis of XLA was confirmed after 17 years, when we finally worked him up for this study. This may be due to the poor understanding of XLA among Chinese physicians.

The *BTK* gene is located at Xq21.3-Xq22 and encompasses 37.5 kb, which contains 19 exons. The first exon of this gene is a noncoding region, and the remaining 18 exons encode the BTK protein \[[@CR13]\]. To date, 911 mutations in the *BTK* gene related to XLA have been deposited in the Human Gene Mutation Database (<http://www.hgmd.cf.ac.uk/ac/gene.php?gene=BTK>). The spectrum of these mutations includes missense mutations, nonsense mutations, splice site mutations, insertions, and deletions, with missense mutation being the most common. It has already been shown that these mutations can occur in the exons, introns, and promoters of the *BTK* gene \[[@CR14], [@CR15]\]. In this study, six novel mutations were found (Table [2](#Tab2){ref-type="table"}): three are point mutations, one is an insertion, and two are deletions. Other mutations that have previously been reported are recurrent mutations.

Patient 7 and Patient 20 died of serious infection during the study follow-up. Patient 6 and Patient 15 were lean, with BMIs of 18.6 kg/m^2^ (1.78 m, 59 kg) and 13.8 kg/m^2^ (1.29 m, 23 kg), respectively. Patient 21 and Patient 22 experienced multiple repeated infections from the time they were 6 months old. Their mutations are large deletions resulting in loss of fragments of the peptide chain, with consequent loss of BTK protein function. The serious condition of these two patients was greatly alleviated once their diagnosis was established and IVIG treatment was initiated. This confirms, as previously reported, the correlation between the patient's genotype and phenotype in XLA \[[@CR16]\]. For Patient 5, the age of onset and diagnosis of XLA was at five years of age. According to his mother, the patient had no signs of a weakened immune system before five years. He has received immunoglobulin injections twice a year and is in reasonable health. The second male fetus harbors the BTK p.T354Pfs\*49 mutation, which is the same mutation carried by his brother (Family 11). Considering the phenotype of the proband, this family chose to continue the pregnancy. Therefore, variable XLA disease manifestation may result depending on the types and sites of *BTK* gene mutations.

XLA is an X-linked recessive genetic disease in which cases are usually male and carriers female. In general, it is very important to screen suspected carriers or cases in the families of patients. The young aunt of Patient 16 carried the c.1631 + 2 T \> C mutation and the sister of Patient 17 p.P560Qfs\*10. Carriers can undergo PGD (preimplantation genetic diagnosis) to know in advance their possibility of conceiving a child with XLA. As a result, some carriers may decide not to have a child. We found that the mothers of the probands in Family 3 and Family 8 did not carry the mutation; hence, p.S38P and p.R255\* are likely de novo mutations.

Conclusion {#Sec12}
==========

In summary, we confirmed the diagnosis of 22 XLA patients from 22 unrelated families by testing for *BTK* gene mutations and discovered six new XLA mutations. We also performed prenatal diagnosis of XLA in six susceptible families. Early genetic diagnosis and routine lifelong immunoglobulin replacement therapy can prevent and treat infections in XLA children and save their lives.
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**Additional file 1: Table S1.***BTK* gene primers.
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